Knee Replacement News and Research

RSS

Viewpoints: Health law will leave some poor families 'in lurch'; Mich. Gov.'s effort to get health exchange

Confusing language in the health care reform law has raised the possibility that millions of Americans living on modest incomes may be unable to afford their employers' family policies and yet fail to qualify for government subsidies to buy their own insurance. This is a bizarre development that undercuts the basic goal of health care reform -; to expand the number of insured people and make their coverage affordable.

28 Aug 2012

AcelRx commences third ARX-01 Phase 3 study in post-operative pain

AcelRx Pharmaceuticals, Inc., a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today announced dosing of the first patient in the third of three planned Phase 3 studies for ARX-01, the Sufentanil NanoTab PCA System, its novel sublingual patient-controlled analgesia (PCA) system.

24 Aug 2012

Acupuncture could save treatment costs and offer viable alternative to knee replacement surgery

The researchers base their findings on 90 patients with knee osteoarthritis, who were referred for group acupuncture to two knee pain clinics in St Albans, Hertfordshire, in 2008 and subsequently monitored for two years.

21 Aug 2012

PPMC earns Gold Seal of Approval for hip and knee joint replacement services

Penn Presbyterian Medical Center (PPMC) has earned the Gold Seal of Approval- from The Joint Commission for its hip and knee joint replacement services. PPMC's certification is the first of its kind for Penn Medicine, and demonstrates the hospital's high level of compliance with The Joint Commission's national standards for health care quality and safety.

15 Aug 2012

Patient, not surgeon factors influence patient-centric outcomes after knee surgery

Patient factors are more important than anything surgeons can control during total knee replacement surgery in the prediction of patient-reported outcome measures, report UK researchers.

9 Aug 2012

Dabigatran ‘still effective in obese’

The oral direct thrombin inhibitor dabigatran is an effective thromboprophylactic therapy for patients undergoing total hip or knee replacement regardless of their body mass index, researchers assert.

9 Aug 2012

Vitamin E total knee replacement performed at Tri-City Medical Center

Dr. James Helgager, an experienced orthopedic surgeon, implanted the first vitamin E Total Knee Replacement in San Diego County on July 31 at Tri-City Medical Center in Oceanside. Helgager is the Medical Director of Joint Replacement for the Orthopaedic & Spine Institute at Tri-City Medical Center. He has been practicing medicine for more than three decades and has performed thousands of total knee replacements.

6 Aug 2012

Increased risk for AMI following hip- and knee-replacement surgery

Elderly patients are at a significantly increased risk for acute myocardial infarction in the 2 weeks following total hip- or knee-replacement surgery, research shows.

27 Jul 2012

Studies look at surgical site infections and hyperglycemia

Two recent studies in the July issues of the Journal of Bone and Joint Surgery (JBJS) looked at surgical site infections and hyperglycemia, the technical term for high blood glucose, or high blood sugar.

26 Jul 2012

NHS hospitals have scope to make efficiency savings by adopting best practice

NHS hospitals have substantial scope to improve their efficiency by adopting best practice, according to research published today by Professor Andrew Street and colleagues at the Centre for Health Economics (CHE) at the University of York.

14 Jul 2012

JRD receives FDA priority review designation for XARELTO sNDAs to treat PE, DVT

Janssen Research & Development, LLC (Janssen R&D) announced today the U.S. Food and Drug Administration (FDA) has assigned a priority review designation to the supplemental New Drug Applications (sNDAs) filed on May 2, 2012 for XARELTO (rivaroxaban), an oral anticoagulant, seeking new indications to treat patients with deep vein thrombosis (DVT), pulmonary embolism (PE), and to prevent recurrent DVT and PE.

9 Jul 2012

Staff at Sheffield Teaching Hospitals shortlisted for more awards than any other trust in the country

Teams of staff at Sheffield Teaching Hospitals have been recognised for their hard work by gaining more shortlisted entries in two high profile national award schemes than any other trust in the country.

25 Jun 2012

Pfizer, Bristol-Myers Squibb receive FDA CRL for ELIQUIS NDA

Bristol-Myers Squibb Company and Pfizer announced that the U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) regarding the New Drug Application (NDA) for ELIQUIS (apixaban) for the prevention of stroke and systemic embolism in patients with nonvalvular atrial fibrillation.

25 Jun 2012

Janssen receives FDA complete response letter for XARELTO sNDA

Janssen Research & Development, LLC (Janssen R&D) announced today the U.S. Food and Drug Administration (FDA) issued a complete response letter regarding a supplemental New Drug Application (sNDA) for XARELTO (rivaroxaban) for the reduction of the risk of secondary cardiovascular events in patients with acute coronary syndrome (ACS).

22 Jun 2012

UCSF's ACT program helps amputees reach their athletic goals

Carlos Gonzalez stands out from an athletic group gathered on a grassy field at the UCSF Mission Bay campus. The gregarious 32-year-old sports a stylish fauxhawk and walks with a confident yet understated swagger. He's training to become a mixed martial arts (MMA) fighter.

6 Jun 2012

BioInvent, ThromboGenics announce results from TB-402 Phase IIb trial on VTE

ThromboGenics NV and co-development partner BioInvent International announce today the results from a Phase IIb trial comparing TB-402, a long acting anticoagulant, against rivaroxaban, an oral anticoagulant.

5 Jun 2012

Arthritis rates set to soar

According to new estimates the number of people with arthritis is set to soar with predictions that 1,500,000 Scots will be living with the condition by 2030.

10 May 2012

Janssen submits XARELTO sNDA with FDA to reduce risk of stent thrombosis in ACS patients

Janssen Research & Development, LLC announced today that it has submitted a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) seeking approval for the use of XARELTO, an oral anticoagulant, to reduce the risk of stent thrombosis in patients with Acute Coronary Syndrome.

10 May 2012

Health law implementation news: Most red states slow walk health exchanges

Politico reports that most GOP-controlled states are holding off on building insurance exchanges until the Supreme Court issues its decision. Meanwhile, the Internal Revenue Service's ability to enforce the health law is the topic of a Capitol Hill hearing and a former White House advisor offers his views during a Madison speech.

20 Apr 2012

Possible link between sleep apnea and post-surgical delirium

An anecdotal observation of a possible link between sleep apnea and post-surgical delirium has been measured and confirmed by a team of researchers at the Duke University Medical Center.

28 Mar 2012